Beta Bionics, Inc.
About Beta Bionics, Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $100.3M
- Net income
- -$73.2M
- Total assets
- $328.7M
- Market cap
- $619.0M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $619.0M
- Shares outstanding
- 44.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 30, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $73.2M in FY2025.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Beta Bionics, Inc..
Write a review
News about Beta Bionics, Inc.
News & sentiment via Polygon.io
